Selected article for: "interquartile range and Lymphocyte count"
Author: D’Ardes, Damiano; Pontolillo, Michela; Esposito, Lucia; Masciarelli, Mara; Boccatonda, Andrea; Rossi, Ilaria; Bucci, Marco; Guagnano, Maria Teresa; Ucciferri, Claudio; Santilli, Francesca; Di Nicola, Marta; Falasca, Katia; Vecchiet, Jacopo; Schael, Thomas; Cipollone, Francesco
Title: Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
  • Cord-id: d44ireu5
  • Document date: 2020_8_31
    • ID: d44ireu5
    Snippet: The diffusion of SARS-CoV-2, starting from China in December 2019, has led to a pandemic, reaching Italy in February 2020. Previous studies in Asia have shown that the median duration of SARS-CoV-2 viral shedding was approximately 12–20 days. We considered a cohort of patients recovered from COVID-19 showing that the median disease duration between onset and end of COVID-19 symptoms was 27.5 days (interquartile range (IQR): 17.0–33.2) and that the median duration between onset of symptoms an
    Document: The diffusion of SARS-CoV-2, starting from China in December 2019, has led to a pandemic, reaching Italy in February 2020. Previous studies in Asia have shown that the median duration of SARS-CoV-2 viral shedding was approximately 12–20 days. We considered a cohort of patients recovered from COVID-19 showing that the median disease duration between onset and end of COVID-19 symptoms was 27.5 days (interquartile range (IQR): 17.0–33.2) and that the median duration between onset of symptoms and microbiological healing, defined by two consecutive negative nasopharyngeal swabs, was 38 days (IQR: 31.7–50.2). A longer duration of COVID-19 with delayed clinical healing (symptom-free) occurred in patients presenting at admission a lower PaO(2)/FiO(2) ratio (p < 0.001), a more severe clinical presentation (p = 0.001) and a lower lymphocyte count (p = 0.035). Moreover, patients presenting at admission a lower PaO(2)/FiO(2) ratio and more severe disease showed longer viral shedding (p = 0.031 and p = 0.032, respectively). In addition, patients treated with corticosteroids had delayed clinical healing (p = 0.013).

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and admission present: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and long clinical: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and lopinavir daily: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute ards respiratory distress syndrome and lymphocyte level: 1, 2, 3, 4
    • acute ards respiratory distress syndrome develop and lopinavir ritonavir: 1
    • acute ards respiratory distress syndrome develop and lymphocyte count: 1, 2
    • additional day and long period: 1
    • additional day and lopinavir ritonavir: 1
    • admission lymphocyte level and lymphocyte count: 1, 2, 3, 4
    • admission lymphocyte level and lymphocyte level: 1, 2, 3, 4
    • admission present and long period: 1
    • admission present and lopinavir ritonavir: 1, 2, 3, 4
    • admission present and low lymphocyte count: 1